

JC06 Rec'd PCT/PTO 24 MAR 2005

10/518732

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that the correspondence to which this certificate is affixed, including each document referred to therein as being enclosed or submitted therewith, is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

By:

*Lewis J. Kreisler*  
Lewis J. Kreisler  
Reg. No. 38522

Date:

*3-22-05*

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor(s):	Robert M. Lorence	Atty. Ref.:	18025-PCTUS
Appl. No.:	10/518,732	Group Art Unit:	Not Assigned
Filed:	December 20, 2004	Examiner:	Not Assigned
For:	ADMINISTRATION OF THERAPEUTIC VIRUSES		

\* \* \* \* \*

March 22, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Examiner is directed to the documents listed on the enclosed Form PTO-1449. A copy of each listed document is enclosed.

In addition, applicants enclose an International Search Report, dated December 28, 2004, in connection with corresponding International Patent Application No. PCT/US03/16474.


This Communication is being filed within three months of the filing date or before the mailing of a first Office Action on the merits. Consideration of this Statement is respectfully requested.

In WO 00/62735, see Example 18 on page 64 and Example 19 on page 65.

Pecora, et al. discusses dosing rates on page 2252, last full paragraph, and in the paragraph bridging pages 2225-2256.

It is believed that no fee is required in connection with the filing of this Statement. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,



Lewis J. Kreisler  
Reg. No. 38522  
Attorney for Applicant(s)

930 Clopper Road  
Gaithersburg, MD 20878  
Phone: (240) 631-2500 x3276  
Facsimile: (240) 683-3794

PTO/SB/08A (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/518,732
Filing Date	December 20, 2004
First Named Inventor	Robert M. Lorence
Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	18025-PCTUS

Sheet		of
-------	--	----

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
		WO94/25627	11-10-1994			
		WO00/62735	10-26-2000			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/518,732
Filing Date	December 20, 2004
First Named Inventor	Robert M. Lorence
Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	18025-PCTUS

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		KIRN, et al., "The Emerging Fields of Suicide Gene Therapy and Virotherapy", Trends in Molecular Medicine", Vol. 8 No. 4 (Suppl.), pages S68-73, 2002.	
		PECORA, et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, an Patients with Advanced Solid Cancer", Journal of Clinical Oncology, Vol. 20, No. 9, pages 2251-2266, May 2002.	
		BERGSLAND, et al., "Shedding Old Paradigms: Developing Viruses to Treat Cancer", Journal of Clinical Oncology, Vol. 20, No. 9, pages 2220-2222, May 2002.	
		ALEXANDER, "Chapter 27: Newcastle Disease, A Laboratory manual for the Isolation and Identification of Avian Pathogens", 3rd Edition, Purchase, et al., eds., (Kendall/Hunt, Iowa), pages 114-120, c1989.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.